Society elects Cherry Wainwright as new President-elect 

The British Pharmacological Society (BPS) is pleased to announce the election of Professor Cherry Wainwright as its new President-elect. 

Professor Cherry Wainwright is Professor Emeritus at Robert Gordon University in Aberdeen. Cherry's research focuses on mechanisms underlying the pathophysiology and the identification of novel therapeutic targets of cardiovascular diseases, and throughout her career has worked closely with the pharmaceutical industry.   

Cherry, who is also a Fellow, has been involved in Society work for many years, most recently serving as Vice President (Meetings), where she has overseen the Society’s return to in-person meetings. 

Cherry will serve a two-year term as President-elect from 1 January 2024 and commence her Presidency on 1 January 2026. She will work alongside Professor Sir Mark Caulfield, who begins his term as President on the same date.  

The BPS welcomes Cherry’s appointment and looks forward to working with her in the coming years.  

Professor Cherry Wainwright said: 

I am honoured and humbled that the membership of the BPS has chosen me as the next President-elect. It is a position of great responsibility, which I will take on with enthusiasm, dedication and a desire to continue the great work of previous holders of this role.

I look forward to working with Mark and the BPS staff team in ensuring that the Society remains at the forefront of our science by providing our membership with a diverse programme of meetings and events, maintaining the quality and diversity of our journals, building partnerships with other organisations and encouraging greater member involvement in our many activities.

Early career researchers play a crucial role in the future of our Society, and I am particularly looking forward to engaging with our ECR community to identify ways in which we can better serve them in their career development.

I am delighted to be working closely with Cherry over the next two years. This is a crucial time for the Society, where we will continue to look at ways to sustain the Society’s work, such as diversifying our income, promoting our journals, and offering an exciting programme of meetings.  

With Cherry as President-elect, I am confident that we can continue to serve our members and deliver on our strategic goals.

As a highly involved and connected member of the Society, Cherry understands what members want and need from the Society. I look forward to working with her and Mark to make sure we can deliver benefits to our members and broaden our reach across the pharmacology community in the years to come.